Direct-acting Antiviral Drug Market by Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase), Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza), Route, Distribution Channel - Global Forecast 2024-2030

Direct-acting Antiviral Drug Market by Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase), Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza), Route, Distribution Channel - Global Forecast 2024-2030


The Direct-acting Antiviral Drug Market size was estimated at USD 10.71 billion in 2023 and expected to reach USD 12.18 billion in 2024, at a CAGR 13.34% to reach USD 25.76 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Direct-acting Antiviral Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Direct-acting Antiviral Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Direct-acting Antiviral Drug Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, Cipla Limited, EVERSANA, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Direct-acting Antiviral Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
NS3/4A Protease

NS5A Protein

NS5B RNA-Dependent RNA polymerase
Indication
Hepatitis C Virus

HIV Infection/ AIDS

Influenza

Prophylaxis
Route
Intravenous

Oral

Subcutaneous

Topical
Distribution Channel
Hospital Pharmacy

Online Drug Store

Retail Pharmacy
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Direct-acting Antiviral Drug Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Direct-acting Antiviral Drug Market?
3. What are the technology trends and regulatory frameworks in the Direct-acting Antiviral Drug Market?
4. What is the market share of the leading vendors in the Direct-acting Antiviral Drug Market?
5. Which modes and strategic moves are suitable for entering the Direct-acting Antiviral Drug Market?PDF E-mail From Publisher (2-5)Users License


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Direct-acting Antiviral Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
5.1.1.2. Rising product development and launch of new direct-acting antiviral medicines
5.1.1.3. Growing awareness and improving healthcare infrastructure in emerging economies
5.1.2. Restraints
5.1.2.1. High cost of direct-acting antiviral drugs
5.1.3. Opportunities
5.1.3.1. Increasing support from government authorities & social healthcare associations for direct-acting antiviral drug
5.1.3.2. Availability of directly-acting antivirals medicines and strategic collaborations among organizations
5.1.4. Challenges
5.1.4.1. Patent expiration of branded direct-acting antiviral
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Direct-acting Antiviral Drug Market, by Type
6.1. Introduction
6.2. NS3/4A Protease
6.3. NS5A Protein
6.4. NS5B RNA-Dependent RNA polymerase
7. Direct-acting Antiviral Drug Market, by Indication
7.1. Introduction
7.2. Hepatitis C Virus
7.3. HIV Infection/ AIDS
7.4. Influenza
7.5. Prophylaxis
8. Direct-acting Antiviral Drug Market, by Route
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
8.5. Topical
9. Direct-acting Antiviral Drug Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Drug Store
9.4. Retail Pharmacy
10. Americas Direct-acting Antiviral Drug Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Direct-acting Antiviral Drug Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Direct-acting Antiviral Drug Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Boehringer Ingelheim International GmbH.
14.1.2. Bristol-Myers Squibb Company
14.1.3. Cipla Limited
14.1.4. EVERSANA
14.1.5. F. Hoffmann-La Roche Ltd.
14.1.6. Merck & Co., Inc.
14.1.7. Novartis AG
14.1.8. Pfizer Inc.
14.1.9. Takeda Pharmaceutical Company Limited
14.1.10. Viatris Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET RESEARCH PROCESS
FIGURE 2. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. DIRECT-ACTING ANTIVIRAL DRUG MARKET DYNAMICS
FIGURE 7. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
FIGURE 12. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings